09.12.2009 • News

Arkema Q1 Sales €1.092 Billion

Arkema announced Q1 sales of €1.092 billion. Q1 Ebitda fell by 64 % to €57 million. Visibility remains very low, and the company cannot see any noticeable improvement in the economic ­environment. Arkema says it confirmed its target to generate a positive free cash flow in 2009 and also confirmed its target to reduce fixed costs by
€550 million in 2010 compared to 2005.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.